Beclabuvir

Beclabuvir 구조식 이미지
카스 번호:
958002-33-0
상품명:
Beclabuvir
동의어(영문):
Beclabuvir;Beclabuvir(BMS-791325);(1aR,12bS)-8-cyclohexyl-N-[(dimethylamino)sulfonyl]-1,1a,2,12b-tetrahydro-11-methoxy-1a-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide;Cycloprop[d]indolo[2,1-a][2]benzazepine-9-carboxamide, 12-cyclohexyl-N-[(dimethylamino)sulfonyl]-4b,5,5a,6-tetrahydro-3-methoxy-5a-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-, (4bS,5aR)-
CBNumber:
CB12717749
분자식:
C36H45N5O5S
포뮬러 무게:
659.84
MOL 파일:
958002-33-0.mol

Beclabuvir 속성

밀도
1.45±0.1 g/cm3(Predicted)
저장 조건
Store at -20°C
용해도
DMSO:30.0(Max Conc. mg/mL);45.46(Max Conc. mM)
물리적 상태
Solid
산도 계수 (pKa)
4.44±0.40(Predicted)
색상
White to off-white

안전

Beclabuvir C화학적 특성, 용도, 생산

개요

Beclabuvir is a non-nucleoside, nonstructural protein 5B (NS5B) polymerase inhibitor approved in Japan as part of a fixed-dose combination product for the treatment of hepatitis C virus (HCV). Upon administration and after intracellular uptake, the drug binds to the allosteric, noncatalytic “Thumb 1” site of NS5B resulting in a decreased rate of viral RNA synthesis and replication.4 Beclabuvir is combined with asunaprevir and declatasvir (both approved in 2014) and was discovered and developed by Bristol-Myers Squibb.

Synthesis

The syntheses of asunaprevir and declatasvir were described in an earlier review article.Condensation of indole-6-carboxylic acid (1) with cyclohexanone under basic conditions gave acid 2 in quantitative yield. Hydrogenation of the double bond in 2 using Pearlman?ˉs catalyst was followed by esterification to give ester 3 in high yield. Bromination of the indole at the 2-position was accomplished with pyridinium tribromide, and this was followed by saponification to provide acid 4. Treatment of 4 with carbonyldiimidazole (CDI) followed by N,N- dimethylsulfamide and 1, 8 - diazabicyclo[5.4.0]undec-7-ene (DBU) gave compound 5 in 74% yield. Suzuki coupling of 5 with commercial boronic acid 6 provided intermediate 7, which converted to hemiaminal 8 upon continued heating in 61% yield. Compound 8 was then treated with methyl 2-(dimethoxyphosphoryl)acrylate (9) to affect a tandem conjugate addition and Horner?Wadsworth? Emmons (HWE) olefination to give ester 10. Alternatively, the Suzuki coupling reaction of 5 with 6 could be stopped at intermediate 7, which could be treated with 9 to promote the tandem conjugate addition/HWE to give 10. Corey?-Chaykovsky cyclopropanation of 10 using sodium hydride and trimethylsulfoxonium iodide followed by chiral separation provided cyclopropane 11 in good yield and >99% enantiomeric excess (ee). Saponification of the methyl ester of 11 followed by coupling with 3-methyl-3,8-diazabicyclo[3.2.1]- octane dihydrochloride (12) gave beclabuvir (I) in high yield.
Synthesis_958002-33-0

Beclabuvir 준비 용품 및 원자재

원자재

준비 용품


Beclabuvir 공급 업체

글로벌( 32)공급 업체
공급자 전화 이메일 국가 제품 수 이점
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 32063 58
InvivoChem
+1-708-310-1919 +1-13798911105
sales@invivochem.cn United States 6391 58
TargetMol Chemicals Inc.

support@targetmol.com United States 38463 58
Wuhan Topule Biopharmaceutical Co., Ltd
+8618327326525
masar@topule.com China 8467 58
Aladdin Scientific
+1-+1(833)-552-7181
sales@aladdinsci.com United States 52925 58
Amadis Chemical Company Limited
571-89925085
sales@amadischem.com China 131957 58
Shanghai Biopharmaleader Co., Ltd. +86 18721201413
sales@biopharmaleader.com China 1720 58
Musechem +1-800-259-7612
info@musechem.com United States 4660 60
Fan De(Beijing) Biotechnology Co., Ltd. 15911056312
liming@bio-fount.com China 9729 58
Hangzhou Synstar pharmaceutical Technology CO.,Ltd 0571-85361029
synstar518@163.com China 1990 58

Copyright 2019 © ChemicalBook. All rights reserved